A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)

Critères d'exclusion

• If prior anticancer therapy is allowed, participants are excluded if they received prior systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) before allocation • Has received prior locoregional therapy within 2 weeks of start of study intervention, or has ongoing locoregional treatment-related toxicities • Is currently receiving any anticoagulants • Was discontinued from prior immunotherapy due to a Grade ≥3 immune-related adverse event (irAE) • Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention • Has known additional malignancy that is progressing or has required active treatment within the past 2 years • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis • Has active autoimmune disease that has required systemic treatment in the past 2 years • Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments • Active or ongoing stomatitis and/or mucositis of any grade • HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease • Hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh class B or more severe liver cirrhosis • Has history of posterior reversible encephalopathy syndrome (PRES) or seizure disorder • Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing • Has history of stem cell/solid organ transplant • Has not adequately recovered from major surgery or from central venous access device placement, or has ongoing surgical complications • Has clinically significant hemoptysis, hematemesis, or tumor bleeding within 4 weeks before the first dose of study intervention • Has any clinically significant or life-threatening bleeding event that occurred within 3 months prior to the first dose of the study intervention • Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage • Has any history of myocarditis or cardiomyopathy • Has a current or history of severe cardiovascular and cerebrovascular diseases